These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
    Author: Farnier M.
    Journal: Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():27-8. PubMed ID: 18001317.
    Abstract:
    Ezetimibe with simvastatin in combination inhibits both the absorption and production of cholesterol. This dual mechanism of inhibition substantially increases the capacity to decrease levels of atherogenic low-density lipoproteins, compared with that observed when either drug is used alone. Ezetimibe/simvastatin is more effective than atorvastatin or rosuvastatin monotherapy treatments in low-density lipoprotein cholesterol lowering and getting more patients to goals. Ezetimibe/simvastatin offers an important treatment alternative to patients who respond inadequately even to high-dose statin therapy.
    [Abstract] [Full Text] [Related] [New Search]